Published in

Wiley, FEBS Letters, 1(567), p. 63-66, 2004

DOI: 10.1016/j.febslet.2004.02.091

Wiley, FEBS Letters, 1(567), p. 63-66

DOI: 10.1016/s0014-5793(04)00375-8

Links

Tools

Export citation

Search in Google Scholar

Immunotherapy and immunoselection - Tumour escape as the final hurdle

Journal article published in 2004 by Graham Pawelec ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Tumours are immunogenic and are commonly infiltrated by anti-cancer effector cells. Why, then, are they not completely rejected by the host? Unfortunately, tumours are Darwinian paragons, winning the battle against the forces of natural immune selection. Some of the latter can even act as double-edged swords, actually being subverted to become pro-tumorigenic. Prevention or reversal of tumour escape from the immune response therefore offers the possibility of reconstituting effective anti-tumour immunity and remains the major challenge for 21st century tumour immunology.